Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00597818 · ClinicalTrials.gov registry record · Phase 2
Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
A Phase 2 study, sponsored by Sucampo Pharma Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT00597818 is a Phase 2 study that has completed, run by Sucampo Pharma Americas. The registered enrollment target is 121 participants.
The verdict
NCT00597818, a Phase 2 study, has completed, sponsored by Sucampo Pharma Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the efficacy and safety of three dose levels of cobiprostone as compared to placebo in OA/RA patients treated with an NSAID for 20 months.
Interventions
- DRUG Placebo
- DRUG Cobiprostone
- DRUG Non-steroidal anti-inflammatory drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00597818
The ClinicalTrials.gov registry entry for NCT00597818 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sucampo Pharma Americas, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00597818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00597818 about?
NCT00597818 is a clinical study titled "Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury". The primary purpose of this study is to determine the efficacy and safety of three dose levels of cobiprostone as compared to placebo in OA/RA patients treated with an NSAID for 20 months.
What is the current status of trial NCT00597818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2007-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00597818?
The interventions under investigation include: Placebo (DRUG), Cobiprostone (DRUG), Non-steroidal anti-inflammatory drug (DRUG).
Who is sponsoring clinical trial NCT00597818?
This trial is sponsored by Sucampo Pharma Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.